Date of Award
2019
Document Type
Thesis
Degree Name
M.S. in Pharmaceutical Science
Department
Pharmaceutics and Drug Delivery
First Advisor
Soumyajit Majumdar
Second Advisor
Eman Ashour
Third Advisor
Michael A. Repka
Relational Format
dissertation/thesis
Abstract
Cyclosporine (CSA) is a highly potent immunosuppressant drug and has been used to treat rheumatoid arthritis, psoriasis, organ rejection post-transplant, and chronic dry eye disease. The objective of this investigation was to increase the CSA residence time on the ocular surface using solid lipid nanoparticles (SLNs) and its in-situ gel formulation (CSA-SLN-IG), for treatment of dry eye disease. CSA loaded SLNs (CSA-SLN) were prepared with the homogenization method, using Precirol ® ATO 5 as a solid lipid and Tween® 80 and Poloxamer 188 as surfactants. Prepared SLNs were optimized based on particle size, zeta potential (ZP), PDI, assay and stability. CSA-SLN in-situ gels (CSA-SLN-IG) were developed using gellan gum as the gelling agent and rheological properties were evaluated. DSC analysis shothat there was no interaction between lipid and drug. Optimized CSA-SLN shothe particle size, PDI, ZP and assay to be121.20± 5.20 nm, 0.4 ±0.04, -24 ± 1, 95 ± 0.5% respectively. CSA-SLN was stable at refrigerated and room temperature conditions over one month and no significant changes were observed before and after autoclaving up to one month. CSA-SLN-IG prepared with 0.3% gellan gum shoimmediate gel formation with a gel residence time of more than 24 hours, the viscosity of 27.90± 2.80 cP and an assay of 85 ± 0.5%.Therefore, CSA-SLN and CSA-SLN-IG could be considered as an alternative approach for dry eye disease.
Recommended Citation
Senapati, Samir Shyambabu, "In-Situ Gel of Cyclosporine A – Loaded Solid Lipid Nanoparticles for Topical Occular Delivery for Dry Eye Disease" (2019). Electronic Theses and Dissertations. 1688.
https://egrove.olemiss.edu/etd/1688